Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

Piper Sandler Maintains Overweight on Black Diamond Therapeutic, Maintains $12 Price Target

Author: Benzinga Newsdesk | July 03, 2024 12:28pm
Piper Sandler analyst Joseph Catanzaro maintains Black Diamond Therapeutic (NASDAQ:BDTX) with a Overweight and maintains $12 price target.

Posted In: BDTX